Navigation Links
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
Date:9/2/2008

NATICK, Mass. and Munich, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the European and Intercontinental launch phases of its global TAXUS OLYMPIA registry, the world's largest post-approval, prospective registry for a single drug-eluting stent (DES). OLYMPIA is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System in the treatment of patients with coronary artery disease. Results from the 22,000-patient study were presented by Oscar Mendiz, M.D., at the European Society of Cardiology Congress in Munich, Germany.

The TAXUS OLYMPIA registry employs a consecutive enrollment process and consists of diverse and high-risk patient populations, reflecting real-world usage patterns found in everyday clinical practice. One-year data were collected for a total of 22,345 patients to date in 57 countries. A large majority of patients (75%) were considered "expanded use" cases consisting of complex lesions or complex clinical characteristics. The overall OLYMPIA population in these two phases included patients with multivessel disease (56.5%), prior PCI (27.9%), prior myocardial infarction (MI) (34.1%), multiple stents (32.3%), and medically treated diabetes (27.0%).

The one-year results demonstrated a low overall 3.8 percent rate of TAXUS Liberte stent-related composite cardiac events, including cardiac death (1.2%), MI (0.8%), and re-intervention (TLR) (2.5%). The definite stent thrombosis rate was 0.8 percent after one year, which is consistent with safety data from other DES registries. In the more complex expanded use patient population, the rates
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
3. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... http://www.researchandmarkets.com/research/7jx6nq/china ) has announced the addition of ...  report to their offering.       ... cardiovascular disease in China ... and changes in consumption concept, dietary habit, ...
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... 17, 2014  Ameritox SM , the nation,s leader ... Thomas Smith , M.D., as Chief Medical Officer. ... offering scientific resources for healthcare providers, patients and managed ... positions at a variety of healthcare companies that have ... pain and behavioral health sides of Ameritox,s business. He ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... Associates, of New Jersey awarded General Program Prize Paper at ... ... 18 Researchers at,Reproductive Medicine Associates of New Jersey (RMA) ... Reproductive Medicine (ASRM),for developing a novel technology making it possible ...
... Corporation,announced today that enrollment has completed in a ... to enhance memory. The,IMPACT ("Improvement in Memory with ... than five hundred adults aged 65+,seeking to improve ... Principal Investigators for the IMPACT trial are Elizabeth ...
Cached Medicine Technology:Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 2Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 3Study Demonstrates Mindful Approach to Aging 2Study Demonstrates Mindful Approach to Aging 3
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Criminal Fine is Largest Individual Corporate Criminal Fine in ... American pharmaceutical giant Eli Lilly and Company today agreed ... its drug Zyprexa for uses not approved by the ... announced today. This resolution includes a criminal ...
... Jan. 15 For the first time in Ohio,s,history, ... in a,statewide effort to make Ohio the safest place ... The Cardinal Health Foundation, the Ohio Business ... and the Ohio Children,s,Hospital Association today announced the formation ...
... to Private FirmsPHILADELPHIA, Jan. 15 /PRNewswire/ -- ... Communications for Centocor, Inc., an operating company of ... of a public relations consultancy, Pitch360 Incorporated ( ... communications, and issues management consultancy that leverages its ...
... BOSTON ─ (January 15, 2009) Tufts University has ... Health (NIH) to design an obesity prevention program ... D. Economos, PhD, the clinical trial will randomize ... age children living in Somerville, Mass., and follow ...
... nonpartisan Employee Benefit Research Institute (EBRI) today published a ... involved in capping the tax exclusion for employment-based health ... year,s expected debate over overhauling the nation,s health care ... been a policy goal of both parties as far ...
... Health Group announced today that in the year ... hospitals with local employers reached more than 70,000 ... rising healthcare costs as America confronts such growing ... At the same time, hospitals partnering with Aegis ...
Cached Medicine News:Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Ohio Business, Health Care Leaders Join Together to Improve Patient Safety, Reduce Costs in Ohio Hospitals 2Health News:Ohio Business, Health Care Leaders Join Together to Improve Patient Safety, Reduce Costs in Ohio Hospitals 3Health News:Former Johnson & Johnson Executive Gives Big Voice to Small Companies 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 3Health News:New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage 2Health News:Hospital-Employer Partnerships Growing as Employers Seek Ways to Improve Health and Manage Dollars in Tough Economic Times 2
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
... 24-well x 0.2ml sub-ambient block and automatic ... Heating rates: up to 3C/second; Accurate block ... uniformity: better than 0.5C within 15 seconds; ... directory program storage of up to 60 ...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
... a high quality, compact thermal cycler. In addition ... Mastercycler personal offers first-rate operational flexibility. Its universal ... x 0.2 ml tubes, 16 x 0.5 ml ... grid format. Like the Mastercycler and the Mastercycler ...
Medicine Products: